co.don Past Earnings Performance

Past criteria checks 0/6

co.don's earnings have been declining at an average annual rate of -15.4%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been growing at an average rate of 10.7% per year.

Key information

-15.4%

Earnings growth rate

1.3%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate10.7%
Return on equity-214.2%
Net Margin-143.5%
Last Earnings Update30 Jun 2022

Recent past performance updates

Recent updates

Here's Why co.don (ETR:CNW) Can Afford Some Debt

Oct 06
Here's Why co.don (ETR:CNW) Can Afford Some Debt

Health Check: How Prudently Does co.don (ETR:CNWK) Use Debt?

May 06
Health Check: How Prudently Does co.don (ETR:CNWK) Use Debt?

Will co.don (ETR:CNWK) Spend Its Cash Wisely?

Mar 15
Will co.don (ETR:CNWK) Spend Its Cash Wisely?

Analysts Expect Breakeven For co.don AG (ETR:CNWK) Before Long

Feb 08
Analysts Expect Breakeven For co.don AG (ETR:CNWK) Before Long

co.don's(ETR:CNWK) Share Price Is Down 85% Over The Past Three Years.

Jan 04
co.don's(ETR:CNWK) Share Price Is Down 85% Over The Past Three Years.

Revenue & Expenses Breakdown

How co.don makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

XTRA:CNW Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2210-14110
31 Mar 2210-12110
31 Dec 2110-9110
30 Sep 218-10110
30 Jun 217-11100
31 Mar 216-13100
31 Dec 206-14100
30 Sep 206-15110
30 Jun 207-16110
31 Mar 207-14100
31 Dec 197-13100
30 Sep 196-1190
30 Jun 196-980
31 Mar 196-780
31 Dec 186-680
30 Sep 186-780
30 Jun 186-880
31 Mar 186-870
31 Dec 176-770
30 Sep 176-660
30 Jun 176-560
31 Mar 176-450
31 Dec 166-450
30 Sep 166-350
30 Jun 166-350
31 Mar 165-340
31 Dec 155-340

Quality Earnings: CNW is currently unprofitable.

Growing Profit Margin: CNW is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: CNW is unprofitable, and losses have increased over the past 5 years at a rate of 15.4% per year.

Accelerating Growth: Unable to compare CNW's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CNW is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).


Return on Equity

High ROE: CNW has a negative Return on Equity (-214.21%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies